secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001299130-24-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173
--------------------------------------------------------------------------------

- Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).
- Shipped 44 Revio systems in Q4, total installed base 173; annualized pull-through ~$385K per system.
- Preliminary Q4 consumables revenue $18.9M (67% from Revio); instrument revenue $35.1M.
- Cash, equivalents, and investments $631M as of Dec 31, 2023.
- Reaffirms 40-50% annual revenue growth target through 2026, aiming for >$500M in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/pacb-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001299130-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer